https://www.thebodypro.com/category/meeting-costs-hiv-care/tag/news

The Latest

selective focus image of Gilead Truvada for PrEP

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
lab testing

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

By Barbara Jungwirth and Myles Helfand
blue pills on blue background

This Week in HIV Research: PrEP Relief

Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.

By Barbara Jungwirth and Myles Helfand
many one dollar bills

This Week in HIV Research: As Pill Burden Drops, Pill Cost Rises

Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.

By Barbara Jungwirth and Myles Helfand
two elderly people sitting and looking at water

This Week in HIV Research: Our Attunement to Aging

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

By Barbara Jungwirth and Myles Helfand
woman in headscarf receiving chemotherapy in yellow room

This Week in HIV Research: A New Year, an Old Enemy

Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.

By Barbara Jungwirth and Myles Helfand
Doctors from HIVMA and IDSA on Capitol Hill

Doctors Meet With Congressional Staff to Push for 'Ending the HIV Epidemic' Budget

At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.

By Sony Salzman
nurse looking at medical chart

This Week in HIV Research: What's in a Blip?

Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.

By Barbara Jungwirth and Myles Helfand
Person picking up prescription from pharmacy

Government Panel Finds PrEP Is Effective, Must Be Available Free of Cost to Patients

The US Preventive Services Task Force released its final ruling in JAMA.

By Kenyon Farrow
Advances in HIV Science Must Not Leave Needs of People Behind, Experts Urge Img

Advances in HIV Science Must Not Leave Needs of People Behind, Experts Urge

As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.

By Sony Salzman